Physician profile
Sreenivas Katragadda
NPI 1972698850
$5,002.20
in general payments reported to CMS, 2019-2025
25 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,751 · 2020: $828 · 2021: $1,151 · 2022: $999 · 2023: $77.10 · 2024: $87.41 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $273.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $933.19 | 2021-2022 | |
| Allergan, INC. | $930.82 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $447.69 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $303.00 | 2019-2022 | |
| Neos Therapeutics, LP | $295.65 | 2019-2021 | |
| Lundbeck LLC | $270.63 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $219.47 | 2019-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $219.29 | 2022 | |
| Vanda Pharmaceuticals INC. | $201.56 | 2019-2020 | |
| Axsome Therapeutics, INC. | $164.51 | 2023-2024 | Auvelity |
| Alkermes, INC. | $160.93 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $158.97 | 2019-2020 | |
| Shire North American Group INC | $112.57 | 2019 | |
| Supernus Pharmaceuticals, INC. | $111.17 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $109.56 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $88.97 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $45.47 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $44.72 | 2019 | |
| Ironshore Pharmaceuticals INC. | $43.26 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $39.54 | 2020-2021 | |
| Almatica Pharma LLC | $29.94 | 2021 | |
| Bausch Health US, LLC | $27.41 | 2022 | |
| Alfasigma USA, INC. | $17.99 | 2022 | |
| Corium, LLC | $13.46 | 2022 | |
| Eisai INC. | $12.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sreenivas Katragadda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.